Benjamin CD - Search Results

1

Variation in the ordered structure of complexes between CD154 and anti-CD154 monoclonal antibodies.

Ferrant JL, Wilson CA, Benjamin CD, Hess DM, Hsu YM, Karpusas M, Roux KH, Taylor FR. Ferrant JL, et al. Among authors: benjamin cd. Mol Immunol. 2002 Sep;39(1-2):77-84. doi: 10.1016/s0161-5890(02)00045-7. Mol Immunol. 2002. PMID: 12213330

2

The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge.

Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, Garber EA, Hess DM, Shapiro RI, Kenyon NS, Harlan DM, Kirk AD, Burkly LC, Taylor FR. Ferrant JL, et al. Among authors: benjamin cd. Int Immunol. 2004 Nov;16(11):1583-94. doi: 10.1093/intimm/dxh162. Epub 2004 Oct 5. Int Immunol. 2004. PMID: 15466914

3

Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.

Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K, Garber E, Hsu YM. Karpusas M, et al. Structure. 2001 Apr 4;9(4):321-9. doi: 10.1016/s0969-2126(01)00590-1. Structure. 2001. PMID: 11525169 Free article.

4

CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes.

Larkin R, Benjamin CD, Hsu YM, Li Q, Zukowski L, Silver RF. Larkin R, et al. Among authors: benjamin cd. Infect Immun. 2002 Aug;70(8):4716-20. doi: 10.1128/IAI.70.8.4716-4720.2002. Infect Immun. 2002. PMID: 12117990 Free PMC article.

5

Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat.

Kover KL, Geng Z, Hess DM, Benjamin CD, Moore WV. Kover KL, et al. Among authors: benjamin cd. Diabetes. 2000 Oct;49(10):1666-70. doi: 10.2337/diabetes.49.10.1666. Diabetes. 2000. PMID: 11016450

6

Regular articles: conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration.

Wang LC, Liu ZY, Gambardella L, Delacour A, Shapiro R, Yang J, Sizing I, Rayhorn P, Garber EA, Benjamin CD, Williams KP, Taylor FR, Barrandon Y, Ling L, Burkly LC. Wang LC, et al. Among authors: benjamin cd. J Invest Dermatol. 2000 May;114(5):901-8. doi: 10.1046/j.1523-1747.2000.00951.x. J Invest Dermatol. 2000. PMID: 10771469 Free article.

7

Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.

Pelletier M, Thompson JS, Qian F, Bixler SA, Gong D, Cachero T, Gilbride K, Day E, Zafari M, Benjamin C, Gorelik L, Whitty A, Kalled SL, Ambrose C, Hsu YM. Pelletier M, et al. J Biol Chem. 2003 Aug 29;278(35):33127-33. doi: 10.1074/jbc.M305754200. Epub 2003 Jun 9. J Biol Chem. 2003. PMID: 12796483 Free article.

8

Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.

Gobburu JV, Tenhoor C, Rogge MC, Frazier DE Jr, Thomas D, Benjamin C, Hess DM, Jusko WJ. Gobburu JV, et al. J Pharmacol Exp Ther. 1998 Aug;286(2):925-30. J Pharmacol Exp Ther. 1998. PMID: 9694951

9

Dual role for TWEAK in angiogenic regulation.

Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu YM, Ambrose C, Zheng TS, Burkly LC. Jakubowski A, et al. Among authors: benjamin cd. J Cell Sci. 2002 Jan 15;115(Pt 2):267-74. doi: 10.1242/jcs.115.2.267. J Cell Sci. 2002. PMID: 11839778

10

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.

Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS, Whitty A. Runkel L, et al. Among authors: benjamin cd. Biochemistry. 2000 Mar 14;39(10):2538-51. doi: 10.1021/bi991631c. Biochemistry. 2000. PMID: 10704203

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page